secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044830
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics reports Q3 net income of $1.4M but raises going concern doubt as cash stands at $3.2M
--------------------------------------------------------------------------------

- Net income $1.4M ($0.16 basic EPS) vs $1.8M a year ago; revenue $14k from NIH grants.
- Operating expenses surged to $5.3M from $1.5M, driven by R&D and G&A increases.
- Cash, cash equivalents, and restricted cash $3.2M; company expects insufficient funds for 12 months.
- Expects ~$10M from Juvenescence warrant exercise via side letter, but still substantial doubt about going concern.
- Lead candidate SER-252 (apomorphine) for Parkinson's planned for clinical testing in 2025; partnership with Enable Injections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224044830/0001493152-24-044830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224044830/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer